Original Research
Published on 18 Mar 2022
CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome
in Renal Pharmacology
- 6,398 views
- 18 citations
Original Research
Published on 18 Mar 2022
in Renal Pharmacology
Mini Review
Published on 20 May 2022
in General Cardiovascular Medicine
Systematic Review
Published on 28 Jun 2022
in General Cardiovascular Medicine
Review
Published on 26 Oct 2022
in Abdominal Transplantation
Review
Published on 06 Feb 2024
in Cardiovascular and Smooth Muscle Pharmacology
Review
Published on 28 Jan 2021
in Cardiovascular Therapeutics
Review
Published on 14 Dec 2021
in Heart Failure and Transplantation
Review
Published on 19 Dec 2023
in General Cardiovascular Medicine
Review
Published on 25 May 2021
in Nephrology
Review
Published on 10 May 2023
in General Cardiovascular Medicine
Review
Published on 28 Apr 2023
in Metabolic Physiology
Original Research
Published on 07 Jan 2025
in Nephrology
Perspective
Published on 22 Feb 2024
in Clinical Diabetes
Review
Published on 21 Nov 2023
in Cardiovascular and Smooth Muscle Pharmacology
Original Research
Published on 23 May 2022
in Cardiovascular Genetics and Systems Medicine
Review
Published on 14 Jun 2024
in Nephrology